Company News 08 Oct 2024 Orthocell Receives Regulatory Approval for Remplir™ in Singapore Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of… Orthocell
Company News 07 Oct 2024 Orthocell Reports Second Consecutive Quarter of Record Revenue Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™. Orthocell
Company News 06 Sep 2024 First Sales of Striate+™ in New and Significant Market of Canada Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the… Orthocell
Company News 05 Sep 2024 Petra Capital Research Report | September 2024 Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and… Orthocell
Company News 29 Jul 2024 Orthocell submits Singapore Regulatory Application for Striate+™ Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore,… Orthocell
Company News 24 Jul 2024 Orthocell Accelerates Global Market Expansion of Striate+™ and Remplir™ With Seven New Regulatory Applications either in progress or planned Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned… Orthocell
Company News 11 Jul 2024 Orthocell Receives Regulatory Approval to Commence Sales of Striate+™ in Canada Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental… Orthocell
Company News 09 Jul 2024 Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million… Orthocell
Company News, Media 14 Jun 2024 Petra Capital Research Report | June 2024 Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share. Orthocell
Company News 11 Jun 2024 Orthocell applies for TGA market approval for SmrtGraft™ Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in… Orthocell
